ORGANIC COMPOSITIONS TO TREAT KRAS-RELATED DISEASES
The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.
1 . A composition comprising a RNAi agent comprising a sense strand and an antisense strand, wherein the antisense strand comprises the nucleotide sequence of SEQ ID NO:548, SEQ ID NO:549, SEQ ID NO:550, SEQ ID NO:551, or SEQ ID NO:552.
2 . The composition of claim 1 wherein the sense strand comprises the nucleotide sequence of SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, or SEQ ID NO:125.
3 . The composition of claim 1 , wherein each strand of the interfering RNA molecule is less than 30 nucleotides per strand.
4 . The composition of claim 1 wherein the RNAi agent comprises one or more modified nucleotides and/or one or more sugar backbone modifications.
5 . The composition of claim 4 wherein the modified nucleotide comprises a 2′-modification.
6 . The compositions of claim 5 wherein the modified nucleotides independently contain 2′-modification selected from the group consisting of: 2′-deoxy, 2′-deoxy-2′-fluoro, 2′-O-methyl, 2′-O-methoxyethyl (2′-O-MOE), 2′-O-aminopropyl (2′-O-AP), 2′-O-dimethylaminoethyl (2′-O-DMAOE), 2′-O-dimethylaminopropyl (2′-O-DMAP), 2′-O-dimethylaminoethyloxyethyl (2′-O-DMAEOE), and 2′-O—N-methylacetamido (2′-O-NMA).
7 . The composition of claim 4 wherein the RNAi agent comprises one or more modified nucleotides and one or more sugar backbone modifications.
8 . The composition of claim 4 wherein the sense strand and/or the antisense strand contains a 3′ overhang.
9 . The composition of claim 4 wherein the sense strand and/or the antisense strand contains a 5′ overhang.
10 . The composition of claim 4 , wherein the interfering RNA molecule at least one blunt end.
11 . The composition of claim 4 wherein the RNAi agent is ligated to one or more agents selected from: diagnostic compound, reporter group, cross-linking agent, nuclease-resistance conferring moiety, natural or unusual nucleobase, lipophilic molecule, cholesterol, lipid, lectin, steroid, uvaol, hecigenin, diosgenin, terpene, triterpene, sarsasapogenin, Friedelin, epifriedelanol-derivatized lithocholic acid, vitamin, carbohydrate, dextran, pullulan, chitin, chitosan, synthetic carbohydrate, oligo lactate 15-mer, natural polymer, low- or medium-molecular weight polymer, inulin, cyclodextrin, hyaluronic acid, protein, protein-binding agent, integrin-targeting molecule, polycationic, peptide, polyamine, peptide mimic, and/or transferrin.
12 . The composition of claim 4 further comprising a pharmaceutically acceptable carrier.
13 . The composition of claim 12 further comprising an additional disease treatment.
14 . The composition of claim 13 wherein the additional disease treatment comprises a second RNAi agent to KRAS.
15 . A method of treating a KRAS-related disease in an individual, comprising the step of administering to the individual a therapeutically effective amount of a composition comprising a RNAi agent comprising a sense strand and an antisense strand, wherein the antisense strand comprises the nucleotide sequence of SEQ ID NO:548, SEQ ID NO:549, SEQ ID NO:550, SEQ ID NO:551, or SEQ ID NO:552.
16 . The method of claim 15 wherein the sense strand comprises the nucleotide sequence of SEQ ID NO:121, SEQ ID NO:122, SEQ ID NO:123, SEQ ID NO:124, or SEQ ID NO:125
17 . The method of claim 15 , wherein the KRAS-related disease is a proliferative disease, cardio-facio-cutaneous (CFC) syndrome or Noonan syndrome.
18 . The method of claim 15 , wherein the method further comprises the step of administering an additional treatment for a proliferative disease, cardio-facio-cutaneous (CFC) syndrome or Noonan syndrome.
19 . The method of claim 15 , wherein the method further comprises the step of administering an additional RNAi agent to KRAS.
20 . A composition comprising a RNAi agent comprising a sense strand and an antisense strand, wherein the antisense strand comprises the nucleotide sequence of Table 1.